• Je něco špatně v tomto záznamu ?

Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective

Z. Sumnik, A. Szypowska, V. Iotova, N. Bratina, V. Cherubini, G. Forsander, S. Jali, JF. Raposo, G. Stipančic, A. Vazeou, H. Veeze, K. Lange, SWEET study group,

. 2019 ; 20 (4) : 434-443. [pub] 20190411

Jazyk angličtina Země Dánsko

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006592

BACKGROUND: Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. METHODS: The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. RESULTS: We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. CONCLUSIONS: Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006592
003      
CZ-PrNML
005      
20200522093051.0
007      
ta
008      
200511s2019 dk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/pedi.12833 $2 doi
035    __
$a (PubMed)30773756
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a dk
100    1_
$a Sumnik, Zdenek $u Department of Pediatrics, Motol University Hospital, Prague, Czech Republic.
245    10
$a Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective / $c Z. Sumnik, A. Szypowska, V. Iotova, N. Bratina, V. Cherubini, G. Forsander, S. Jali, JF. Raposo, G. Stipančic, A. Vazeou, H. Veeze, K. Lange, SWEET study group,
520    9_
$a BACKGROUND: Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. METHODS: The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. RESULTS: We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. CONCLUSIONS: Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a krevní glukóza $x analýza $7 D001786
650    _2
$a selfmonitoring glykemie $x ekonomika $x přístrojové vybavení $7 D015190
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a osobní újma zaviněná nemocí $7 D017281
650    _2
$a náklady a analýza nákladů $7 D003365
650    _2
$a diabetes mellitus 1. typu $x krev $x farmakoterapie $x ekonomika $x epidemiologie $7 D003922
650    _2
$a zdravotnické prostředky $x ekonomika $7 D004864
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x aplikace a dávkování $x ekonomika $7 D007004
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a inzulin $x aplikace a dávkování $x ekonomika $7 D007328
650    _2
$a inzulinové infuzní systémy $x ekonomika $7 D007332
650    12
$a úhrada zdravotního pojištění $x ekonomika $x statistika a číselné údaje $x trendy $7 D007349
650    _2
$a vynálezy $x ekonomika $x statistika a číselné údaje $x trendy $7 D062069
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Szypowska, Agnieszka $u Department of Pediatrics, Medical University of Warsaw, Warsaw, Poland.
700    1_
$a Iotova, Violeta $u Department of Pediatrics, Medical University-Varna, UMHAT "Sv. Marina", Varna, Bulgaria.
700    1_
$a Bratina, Natasa $u Department of Endocrinology, Diabetes and Metabolism, UMC, University Children's Hospital, Ljubljana, Slovenia.
700    1_
$a Cherubini, Valentino $u Department of Women's and Children's Health, Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, "G. Salesi" Hospital, Ancona, Italy.
700    1_
$a Forsander, Gun $u Institute for Clinical Sciences, Dept of Ped, University of Gothenburg and the Queen Silvia Children's Hospital, Sahlgrenska Univ. Hospital, Gothenburg, Sweden.
700    1_
$a Jali, Sujata $u Department of Pediatrics, KLE University's Jawaharlal Nehru Medical College Belgaum, Belgaum, India.
700    1_
$a Raposo, Joao Felipe $u APDP-Diabetes Portugal and Nova Medical School, Lisbon, Portugal.
700    1_
$a Stipančic, Gordana $u Department of Pediatrics, University Hospital Center "Sestre milosrdnice", School of Dental Medicine, University of Zagreb, Zagreb, Croatia.
700    1_
$a Vazeou, Andriani $u Department of Pediatrics, Diabetes Center, P & A Kyriakou Children's Hospital, Athens, Greece.
700    1_
$a Veeze, Henk $u Diabeter, Rotterdam, The Netherlands.
700    1_
$a Lange, Karin $u Department of Medical Psychology, Hannover Medical School, Hannover, Germany.
710    2_
$a SWEET study group
773    0_
$w MED00181048 $t Pediatric diabetes $x 1399-5448 $g Roč. 20, č. 4 (2019), s. 434-443
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30773756 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200522093049 $b ABA008
999    __
$a ok $b bmc $g 1525450 $s 1096648
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 20 $c 4 $d 434-443 $e 20190411 $i 1399-5448 $m Pediatric diabetes $n Pediatr Diabetes $x MED00181048
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace